Best Healthcare Stocks to Buy in 2026
(NASDAQ: BIIB) and Novo Nordisk (NYSE: NVO) represent different opportunities within the healthcare sector: One is a value-oriented play focusing on specialized neurology, while the other is a high-growth leader in the metabolic health revolution. However, both pharmaceutical companies stand to benefit from new indications for approved therapies that haven't fully been priced into their shares.
Biogen is awaiting approval of Leqembi in a subcutaneous formulation to treat Alzheimer's patients; the drug is already approved in intravenous (IV) formulations. Novo Nordisk is seeing an uptick in Wegovy sales because its weight-loss therapy is now available in pill form. Biogen's shares are trading up more than 13.5% this year, while Novo Nordisk's are down almost 8%.
Here are three reasons why I like each stock.
Source Fool.com
Biogen Inc. Stock
The stock is an absolute favorite of our community with 31 Buy predictions and no Sell predictions.
With a target price of 185 € there is a slightly positive potential of 11.61% for Biogen Inc. compared to the current price of 165.76 €.
